Examination of tumor molecular characteristics by liquid biopsy is likely to greatly influence
personalized cancer patient management. Analysis of circulating tumor DNA (ctDNA) …

Liquid Biopsy in Tumor Genetic Diagnosis - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …

Abstract Purpose: About 60% of non–small cell lung cancer (NSCLC) patients develop
resistance to targeted epidermal growth factor receptor (EGFR) inhibitor therapy through the …

Introduction The genomic alterations driving resistance to third-generation EGFR tyrosine
kinase inhibitors (TKIs) are not well established, and collecting tissue biopsy samples poses …

An increasing number of promising immunotherapies and related clinical trials have led to
several major breakthroughs in multiple cancers, but a reliable and precise biomarker for …

Targeted therapies are revolutionizing the treatment of advanced non-small cell lung cancer
(NSCLC). The discovery of key oncogenic events mainly in lung adenocarcinoma, like …

ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell
lung cancer in real-world setting - PMC Back to Top Skip to main content NIH NLM Logo …

Background: Many studies have evaluated the accuracy of EGFR mutation status in blood
against that in tumor tissues as the reference. We conducted this systematic review and …

Interventions: EGFR-TKIs (Icotinib), MET inhibitor crizotinib. Outcomes: After a progression-
free survival of 9 months and 23months, respectively, both cases progressed accompanying …

ЕGFR (Epidermal growth factor receptor), являясь продуктом одного из онкогенов
семейства erb–с-erbВ1, регулирует клеточную пролиферацию и злокачественную …